[{"data":1,"prerenderedAt":207},["ShallowReactive",2],{"drug-finerenone":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":51,"contraindications":98,"warnings":108,"renal":116,"monitoring":117,"interactions":118,"review":119,"examples":122,"atc":132,"iran":134,"usApproval":150,"links":156,"populations":172},"finerenone",1,{"fa":7,"en":8},"فینرنون","Finerenone","cardiovascular",{"fa":11,"en":12},"آنتاگونیست غیراستروئیدی گیرنده مینرالوکورتیکوئید","Non-steroidal mineralocorticoid receptor antagonist",[14],{"name":15,"market":16},"Kerendia","US",[18,19,7],"kerendia","کرندیا",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-10","tablet","oral","10 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},10,"mg",false,[16],[32],{"source":33,"section":34},"fda-kerendia","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-20","20 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},20,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-40","40 mg tablet",{"amount":47,"unit":28,"perUnit":23,"scored":29},40,[16],[50],{"source":33,"section":34},[52,78],{"id":53,"disease":54,"label":55,"population":58,"type":62,"unit":28,"dose":63,"refs":64,"notes":69},"ckd","diabetic-nephropathy",{"fa":56,"en":57},"بیماری مزمن کلیه با دیابت — eGFR ≥۶۰: ۲۰ mg؛ ۲۵ تا \u003C۶۰: ۱۰ mg یک بار در روز (هدف ۲۰ mg)","CKD with diabetes — eGFR ≥60: 20 mg; 25–\u003C60: 10 mg once daily (target 20 mg)",{"minAge":59},{"value":60,"unit":61},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":5},[65,67],{"source":33,"section":66},"2.2, Table 1",{"source":33,"section":68},"2.3",[70],{"text":71,"refs":74},{"fa":72,"en":73},"پتاسیم پیش از شروع: بالای ۵ شروع نشود. افزایش به ۲۰ mg پس از ۴ هفته طبق پتاسیم و eGFR. eGFR زیر ۲۵ شروع توصیه نمی‌شود.","Check potassium before starting: do not start if >5.0. Increase to 20 mg after 4 weeks per potassium and eGFR. eGFR \u003C25: initiation not recommended.",[75,77],{"source":33,"section":76},"2.1",{"source":33,"section":68},{"id":79,"disease":80,"label":81,"population":84,"type":62,"unit":28,"dose":86,"refs":87,"notes":89},"hf","heart-failure",{"fa":82,"en":83},"نارسایی قلبی با LVEF ≥۴۰٪ — شروع ۱۰ یا ۲۰ mg، هدف ۲۰ یا ۴۰ mg","Heart failure with LVEF ≥40% — start 10 or 20 mg, target 20 or 40 mg",{"minAge":85},{"value":60,"unit":61},{"perDose":39,"perDoseMax":47,"dosesPerDay":5},[88],{"source":33,"section":68},[90],{"text":91,"refs":94},{"fa":92,"en":93},"شروع بر اساس eGFR طبق جدول ۱؛ افزایش پس از ۴ هفته طبق پتاسیم و eGFR.","Start per eGFR (Table 1); increase after 4 weeks per potassium and eGFR.",[95,97],{"source":33,"section":96},"2.2",{"source":33,"section":68},[99],{"id":100,"severity":101,"text":102,"refs":105},"ci","block",{"fa":103,"en":104},"حساسیت به دارو؛ مهارکننده قوی CYP3A4 همزمان؛ نارسایی آدرنال.","Hypersensitivity; concomitant strong CYP3A4 inhibitors; adrenal insufficiency.",[106],{"source":33,"section":107},"4",[109],{"text":110,"refs":113},{"fa":111,"en":112},"هیپرکالمی — پتاسیم پیش از شروع و دوره‌ای.","Hyperkalaemia — check potassium before starting and periodically.",[114],{"source":33,"section":115},"5",[],[],[],{"status":120,"reviewer":121,"date":121},"unverified",null,[123,128],{"regimen":53,"formulation":22,"input":124,"expect":127},{"ageYears":125,"weightKg":126},60,80,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},{"regimen":79,"formulation":36,"input":129,"expect":131},{"ageYears":130,"weightKg":126},70,{"perDose":39,"tabletsPerDoseRounded":5,"upperPerDose":47},[133],"C03DA05",{"status":135,"forms":136,"refs":145},"registered",[137,141],{"code":138,"en":139,"fa":140},"53636","FINERENONE 10 mg TABLET","قرص فینرنون ۱۰ میلی‌گرم",{"code":142,"en":143,"fa":144},"53637","FINERENONE 20 mg TABLET","قرص فینرنون ۲۰ میلی‌گرم",[146],{"source":147,"section":148,"url":149},"darooyab-generic","G-5551\u002FFinerenone","https:\u002F\u002Fwww.darooyab.ir\u002FG-5551\u002FFinerenone",{"kind":151,"refs":152,"id":155},"NDA",[153],{"source":33,"section":154},"SPL approval \u002F marketing category","NDA215341",[157,160,164,167,170],{"kind":158,"url":159,"label":155},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=215341",{"kind":161,"url":162,"label":163},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c","FDA Kerendia",{"kind":165,"url":166,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa621038.html",{"kind":168,"url":169,"label":133},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C03DA05",{"kind":171,"url":149,"label":8},"darooyab",{"pregnancy":173,"lactation":182,"pediatric":190,"geriatric":198},{"level":174,"text":175,"quote":178,"refs":179},"caution",{"fa":176,"en":177},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on Kerendia use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.",[180],{"source":33,"section":181},"8.1",{"level":174,"text":183,"quote":186,"refs":187},{"fa":184,"en":185},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of finerenone or its metabolite in human milk, the effects on the breastfed infant or the effects of the drug on milk production.",[188],{"source":33,"section":189},"8.2",{"level":174,"text":191,"quote":194,"refs":195},{"fa":192,"en":193},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of Kerendia have not been established in patients below 18 years of age.",[196],{"source":33,"section":197},"8.4",{"level":199,"text":200,"quote":203,"refs":204},"ok",{"fa":201,"en":202},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dose adjustment is required.",[205],{"source":33,"section":206},"8.5",1792156178701]